RE
NKTR icon

RBC Europe’s Nektar Therapeutics NKTR Stock Holding History

RBC Europe’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-17
Closed -$6K – 1150
2017
Q3 		$6K Buy
+17
New +$5.32K ﹤0.01% 928

Other funds holding NKTR

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

RBC Europe's NKTR Position: Q4 2017 in Review

RBC Europe sold out of Nektar Therapeutics (NKTR) in Q4 2017, closing a stake of 17 shares — an estimated $6K sold.

RBC Europe first reported a position in NKTR in Q3 2017 and held it in 1 quarter. The position peaked at $6K in Q3 2017. 265 funds tracked by Wall St. Rank hold NKTR as of Q4 2017.

  • RBC Europe reported no remaining Nektar Therapeutics position as of Q4 2017 after selling out during the quarter.
  • RBC Europe sold 17 Nektar Therapeutics shares in Q4 2017, an estimated $6K.
  • RBC Europe first reported a position in Nektar Therapeutics in Q3 2017 and held it in 1 quarter.
  • RBC Europe's Nektar Therapeutics position peaked at $6K in Q3 2017.
  • 265 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2017.

Based on RBC Europe's 13F filing for Q4 2017, filed 9 Nov 2023.